IgA Nephropathy: Early Signs & Symptoms, Disease Burden, & Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Rare Kidney Diseases
Exploring the Scientific Evidence for the Role of Cytokines in the Pathogenesis of IgA Nephropathy
The physiological function of APRIL in B-cell regulation, and the growing body of evidence supporting APRIL inhibition as a potential therapeutic approach. Read MoreIgA Nephropathy: Early Signs & Symptoms, Disease Burden, & Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read MoreIgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
The goal of this event is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read More4 Part IgAN Experience
Recognize the role of B cells in immune-mediated kidney disease. Review current and emerging B-cell-targeted strategies. Read More4 Part IgAN Experience
Explore the physiologic function of APRIL in B-cell regulation. Read More4 Part IgAN Experience
Featuring Andrea Mohindra, PharmD and Jai Radhakrishnan, MD, MS are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Andrew Bomback, MD, MPH is a speaker for Otsuka Pharmaceutical Development… Read More4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. Read MoreKDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 3)
The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD. Read MoreKDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 2)
The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD. Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
